Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

By J. Larkin, P. Ascierto, B. Dréno, V. Atkinson, G. Liszkay, M. Maio, M. Mandalà, L. Demidov, D. Stroyakovskiy, L. Thomas and 9 more. New England Journal of Medicine, 2014

1,976 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/18750b4840625e60bfcec072fabb7189231334b6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “331,337,521 However, the rapid development of drug resistance has limited the use of these drugs in cancer therapy, resulting in temporary bene ﬁ ts lasting from several months to less than 2 years.”
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015, neutral): “(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “Similarly, the inhibition of CSF-1 receptor (CSF-1R) is being use as strategy to inhibit tumor proliferation mediated by MDSCs [83,86,87].”
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Based on the recent data of anti-PD1 efficacy in PDL-1-positive advanced melanoma [41], this parameter, which is determined by immunohistochemistry and reflects the presence of T cells in the tumour microenvironment, might soon be relevant.”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “68) 9mth: 73% 8% 9% reduction skin cancer 4* [145]”
Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “One effort involves multiple agents that target different molecules in the same pathway, such as the combination of a BRAF inhibitor and a MEK-inhibitor (Larkin et al., 2014; Robert et al., 2015a).”
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) (2017, positive): “Vemurafenib (Zelboraf ® ) in melanoma is directed against mutations of BRAF V600E (134) with a successful response of 48% during treatment (127).”